Filter your results
- 3
- 1
- 1
- 1
- 1
- 3
- 1
- 2
- 2
- 1
- 3
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
|
|
sorted by
|
Valeurs toxicologiques de référence (VTR) - Elaboration de VTR par voie respiratoire pour l’acroléine (CAS n°107-02-8)[0] Autosaisine n°2021-MPEX-0149, Anses. 2022, 91 p
Reports
anses-04071363v1
|
|||
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).The Lancet Infectious Diseases, 2015, 15 (4), pp.397-404. ⟨10.1016/S1473-3099(15)70050-2⟩
Journal articles
hal-01134440v1
|
|||
LP28 : Efficacy of the oral sofosbuvir-based combinations in HCV genotype 4-mono-infected patients from the french observational cohort anrs CO22 hepatherThe International Liver Congress™ 2015 – 50th Annual meeting of the European Association for the Study of the Liver, Apr 2015, Vienne, Austria. 62, Supplement 2, pp.S278, 2015, ⟨10.1016/S0168-8278(15)30182-3⟩
Conference poster
hal-01162770v1
|